Yoshiya Tanaka
Researcher Next ID · RN-023000
Researcher · Medicine
Minneapolis, Japan
- Works count
- 1,687
- Citation count
- 57,844
- H-index
- 104
- i10-index
- 761
Research interests
Publications
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update
Annals of the Rheumatic Diseases · 2024 · 10.1136/ard-2024-225531
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Annals of the Rheumatic Diseases · 2023 · https://doi.org/10.1136/ard-2023-224762
Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis
Nature Genetics · 2022 · 10.1038/s41588-022-01213-w
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach
Nature Reviews Rheumatology · 2022 · 10.1038/s41584-021-00726-8
Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Respiratory Medicine · 2020 · https://doi.org/10.1016/s2213-2600(20)30318-0
2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus
Annals of the Rheumatic Diseases · 2019 · https://doi.org/10.1136/annrheumdis-2018-214819
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1912196
2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus
Arthritis & Rheumatology · 2019 · https://doi.org/10.1002/art.40930
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
The Lancet · 2019 · 10.1016/s0140-6736(19)30419-2
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
The Lancet · 2018 · 10.1016/s0140-6736(18)31363-1
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials
Annals of the Rheumatic Diseases · 2017 · 10.1136/annrheumdis-2016-210457
Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)
Annals of the Rheumatic Diseases · 2017 · 10.1136/annrheumdis-2017-211878
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
New England Journal of Medicine · 2017 · 10.1056/nejmoa1608345
Janus kinase inhibitors in autoimmune diseases
Annals of the Rheumatic Diseases · 2013 · 10.1136/annrheumdis-2012-202576
Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study
Arthritis & Rheumatism · 2013 · 10.1002/art.37816
Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011
Modern Rheumatology · 2012 · 10.1007/s10165-011-0571-z
Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011
Modern Rheumatology · 2012 · 10.3109/s10165-011-0571-z
A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details
Modern Rheumatology · 2012 · 10.3109/s10165-011-0508-6
A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details
Modern Rheumatology · 2011 · 10.1007/s10165-011-0508-6
Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis
Annals of the Rheumatic Diseases · 2007 · 10.1136/ard.2007.072967
Osteoblasts and Osteoclasts in Bone Remodeling and Inflammation
Current Drug Targets - Inflammation & Allergy · 2005 · 10.2174/1568010054022015
T-cell adhesion induced by proteoglycan-immobilized cytokine MIP-lβ
Nature · 1993 · 10.1038/361079a0
Proteoglycans on endothelial cells present adhesion-inducing cytokines to leukocytes
Immunology Today · 1993 · 10.1016/0167-5699(93)90209-4
CD31 expressed on distinctive T cell subsets is a preferential amplifier of beta 1 integrin-mediated adhesion.
The Journal of Experimental Medicine · 1992 · 10.1084/jem.176.1.245
Lymphocyte interactions with endothelial cells
Immunology Today · 1992 · 10.1016/0167-5699(92)90151-v
Current projects
No projects listed.